. La-situation-du-cancer-en-france-en, Collection Rapports & synthèses, ouvrage collectif édité par l'INCa, 2011.

E. Quoix and E. Lemarié, ??pid??miologie du cancer bronchique primitif??: aspects classiques et nouveaut??s, Revue des Maladies Respiratoires, vol.28, issue.8, pp.1048-58, 2011.
DOI : 10.1016/j.rmr.2010.12.015

. Ministère-de-l-'enseignement-supérieur-et-de-la-recherche, Ministère de la Santé et des Sports. Plan cancer, 2009.

J. Chevallier, ANATOMIE Tome 1 Le tronc. Paris: Médecine-Sciences Flammarion, 1998.

M. Riquet, Anatomie du poumon humain, EMC - Pneumologie, vol.9, issue.3, pp.1-11, 2012.
DOI : 10.1016/S1155-195X(12)50830-3

G. Cordier and C. Cabrol, Les pédicules segmentaires du poumon

. Paris, Expansion Scientifique, 1952.

G. Cordier and C. Cabrol, Les pédicules segmentaires du poumon. Tome II poumon gauche

. Paris, Expansion Scientifique, 1955.

N. Bossard, M. Velten, L. Remontet, A. Belot, N. Maarouf et al., Survie des patients atteints de cancer en France : étude à partir des données des registres du réseau Francim, BEH, pp.9-1066, 2007.

L. Thiberville and C. Paris, Épidémiologie et facteurs de risque des cancers bronchiques primitifs, EMC, vol.Pneumologie, p.8, 2004.
DOI : 10.1016/j.emcpn.2003.10.002

R. Doll and A. Hill, Study of the Aetiology of Carcinoma of the Lung, BMJ, vol.2, issue.4797, pp.1271-86, 1952.
DOI : 10.1136/bmj.2.4797.1271

E. Wynder and E. Graham, TOBACCO SMOKING AS A POSSIBLE ETIOLOGIC FACTOR IN BRONCHIOGENIC CARCINOMA, Journal of the American Medical Association, vol.143, issue.4, pp.329-365, 1950.
DOI : 10.1001/jama.1950.02910390001001

S. Benhamou, E. Benhamou, M. Tirmarche, and R. Flamant, Lung cancer and use of cigarettes : a French case-control study, J Natl Cancer Inst, vol.74, issue.6, pp.1169-75, 1985.

L. Simonato, A. Agudo, W. Ahrens, E. Benhamou, S. Benhamou et al., Lung cancer and cigarette smoking in Europe: An update of risk estimates and an assessment of inter-country heterogeneity, International Journal of Cancer, vol.11, issue.6, pp.876-87, 2001.
DOI : 10.1093/aje/152.1.32

C. Hill, E. Jougla, and F. Beck, Le point sur l'épidémie de cancer du poumon dû au tabagisme, BEH, pp.19-20211, 2010.

R. Doll, R. Peto, K. Wheatley, R. Gray, and I. Sutherland, Mortality in relation to smoking: 40 years' observations on male British doctors, BMJ, vol.309, issue.6959, pp.901-912, 1994.
DOI : 10.1136/bmj.309.6959.901

R. Doll, R. Peto, J. Boreham, and I. Sutherland, Mortality in relation to smoking: 50 years' observations on male British doctors, BMJ, vol.328, issue.7455, p.1519, 2004.
DOI : 10.1136/bmj.38142.554479.AE

M. Halpern, B. Gillespie, and K. Warner, Patterns of Absolute Risk of Lung Cancer Mortality in Former Smokers, JNCI Journal of the National Cancer Institute, vol.85, issue.6, pp.457-64, 1993.
DOI : 10.1093/jnci/85.6.457

N. Wirth, A. Bohadana, A. Spinosa, and Y. Martinet, Les pathologies respiratoires li??es au tabagisme passif, Revue des Maladies Respiratoires, vol.26, issue.6, pp.667-78, 2009.
DOI : 10.1016/S0761-8425(09)74696-0

A. Hackshaw, M. Law, and W. N. , The accumulated evidence on lung cancer and environmental tobacco smoke, BMJ, vol.315, issue.7114, pp.980-988, 1997.
DOI : 10.1136/bmj.315.7114.980

L. Zhong, M. Goldberg, M. Parent, and J. Hanley, Exposure to environmental tobacco smoke and the risk of lung cancer: a meta-analysis, Lung Cancer, vol.27, issue.1, pp.3-18, 2000.
DOI : 10.1016/S0169-5002(99)00093-8

J. Gamble, Lung cancer and diesel exhaust: A critical review of the occupational epidemiology literature, Critical Reviews in Toxicology, vol.13, issue.3, pp.189-244, 2010.
DOI : 10.1080/15298669191365162

J. Gamble, M. Nicolich, and P. Boffetta, Lung cancer and diesel exhaust: an updated critical review of the occupational epidemiology literature, Critical Reviews in Toxicology, vol.6, issue.1, pp.549-98, 2012.
DOI : 10.1021/es990903w

URL : https://hal.archives-ouvertes.fr/hal-01263002

N. Guha, F. Merletti, N. Steenland, A. Altieri, V. Cogliano et al., Lung Cancer Risk in Painters: A Meta-Analysis, Environmental Health Perspectives, vol.118, issue.3, pp.303-315, 2010.
DOI : 10.1289/ehp.0901402.s1

A. Olsson, J. Fevotte, T. Fletcher, A. Cassidy, A. Mannetje et al., Occupational exposure to polycyclic aromatic hydrocarbons and lung cancer risk: a multicenter study in Europe, Occupational and Environmental Medicine, vol.67, issue.2, pp.98-103, 2010.
DOI : 10.1136/oem.2009.046680

H. Bégueret, Anatomie pathologique des cancers bronchopulmonaires, EMC - Pneumologie, vol.5, issue.2, pp.6-8, 2008.
DOI : 10.1016/S1155-195X(08)47943-4

W. Travis, E. Brambilla, H. Müller-hermelink, and C. Harris, World Healt Organization Classification of Tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart, 2004.

. Cancer-du-poumon and . Bilan-initial, Collection Recommandations et référentiels, ouvrage collectif édité par l'INCa, 2011.

P. Goldstraw, J. Crowley, K. Chansky, D. Giroux, P. Groome et al., The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, Journal of Thoracic Oncology, vol.2, issue.8, pp.706-720, 2007.
DOI : 10.1097/JTO.0b013e31812f3c1a

P. Groome, V. Bolejack, J. Crowley, C. Kennedy, M. Krasnik et al., The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, Journal of Thoracic Oncology, vol.2, issue.8, pp.694-705, 2007.
DOI : 10.1097/JTO.0b013e31812d05d5

K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata et al., Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials, Annals of Oncology, vol.15, issue.12, pp.1782-1791, 2004.
DOI : 10.1200/JCO.1996.14.1.127

A. Ardizzoni, L. Boni, M. Tiseo, F. Fossella, J. Schiller et al., Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis, JNCI Journal of the National Cancer Institute, vol.47, issue.1, pp.847-57, 2007.
DOI : 10.1016/j.lungcan.2004.10.014

K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata et al., Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.22, issue.19, pp.3852-3861, 2004.
DOI : 10.1200/JCO.2004.02.109

L. Chevalier, T. Scagliotti, G. Natale, R. Danson, S. Rosell et al., Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes, Lung Cancer, vol.47, issue.1
DOI : 10.1016/j.lungcan.2004.10.014

J. Dancey, F. Shepherd, R. Gralla, and Y. Kim, Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial, Lung Cancer, vol.43, issue.2, pp.183-94, 2004.
DOI : 10.1016/j.lungcan.2003.09.001

A. Sandler, R. Gray, M. Perry, J. Brahmer, J. Schiller et al., Paclitaxel???Carboplatin Alone or with Bevacizumab for Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.355, issue.24, pp.2542-50, 2006.
DOI : 10.1056/NEJMoa061884

M. Reck, V. Pawel, J. Zatloukal, P. Ramlau, R. Gorbounova et al., Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non???Small-Cell Lung Cancer: AVAiL, Journal of Clinical Oncology, vol.27, issue.8, pp.1227-1261, 2009.
DOI : 10.1200/JCO.2007.14.5466

T. Mitsudomi, T. Kosaka, and Y. Yatabe, Biological and clinical implications of EGFR mutations in lung cancer, International Journal of Clinical Oncology, vol.11, issue.Suppl 1, pp.190-198, 2006.
DOI : 10.1053/sonc.2002.35642

R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal et al., Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer, New England Journal of Medicine, vol.361, issue.10, pp.958-67, 2009.
DOI : 10.1056/NEJMoa0904554

D. Jackman, V. Miller, L. Cioffredi, B. Yeap, P. Jänne et al., Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials, Clinical Cancer Research, vol.15, issue.16, pp.5267-73, 2009.
DOI : 10.1158/1078-0432.CCR-09-0888

J. Carlson, L. Garrison, S. Ramsey, and D. Veenstra, Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis, Journal of Cancer Research and Clinical Oncology, vol.2, issue.2, pp.1483-93, 2009.
DOI : 10.4161/cc.4.10.2105

S. Morita, I. Okamoto, K. Kobayashi, K. Yamazaki, H. Asahina et al., Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-Small Cell Lung Cancer with EGFR Mutations, Clinical Cancer Research, vol.15, issue.13, pp.4493-4501, 2009.
DOI : 10.1158/1078-0432.CCR-09-0391

. Ministère-de-la-santé-et-des-solidarités, Décret n° 2005-1023 du 24 août 2005 relatif au contrat de bon usage des médicaments et des produits et prestations mentionné à l'article L. 162-22-7 du code de la sécurité sociale (troisième partie : Décrets) [en ligne], Disponibilité sur Internet, 2005.

A. Inca and H. , Référentiel de bon usage de la liste hors GHS : cancers bronchiques et mésothéliomes pleuraux malins [en ligne]. Mars, Disponibilité sur Internet, 2012.

M. Reck, V. Pawel, J. Zatloukal, P. Ramlau, R. Gorbounova et al., Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL), Annals of Oncology, vol.3, issue.3, pp.1804-1813, 2010.
DOI : 10.1016/j.ccr.2008.08.001

D. Johnson, L. Fehrenbacher, W. Novotny, R. Herbst, J. Nemunaitis et al., Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.22, issue.11, pp.2184-91, 2004.
DOI : 10.1200/JCO.2004.11.022

R. Zinner, F. Fossella, G. Gladish, B. Glisson, G. Blumenschein et al., Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer, Cancer, vol.20, issue.11, pp.2449-56, 2005.
DOI : 10.4161/cbt.1.5.223

G. Scagliotti, C. Kortsik, G. Dark, A. Price, C. Manegold et al., Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial, Clin Cancer Res, vol.11, issue.2, pp.690-696, 2005.

. Randomized, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group, J Clin Oncol, vol.21, issue.16, pp.3016-3040, 2003.

F. Fossella, Docetaxel in Second-Line Treatment of non???small-Cell Lung Cancer, Clinical Lung Cancer, vol.3, issue.2, pp.23-28, 2002.
DOI : 10.3816/CLC.2002.s.010

K. Kasahara, H. Kimura, K. Shibata, T. Araya, T. Sone et al., A phase II study of combination chemotherapy with docetaxel and carboplatin for patients with advanced or metastatic non-small cell lung cancer, Anticancer Res, vol.26, issue.5B, pp.3723-3731, 2006.

O. Anagnostopoulou, Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial, J Clin Oncol, vol.23, issue.13, pp.2937-2982, 2005.

K. Kiura, H. Ueoka, Y. Segawa, M. Tabata, H. Kamei et al., Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer, British Journal of Cancer, vol.16, issue.Suppl 2, pp.795-802, 2003.
DOI : 10.1200/JCO.1998.16.5.1948

P. Brunsvig, R. Hatlevoll, R. Berg, G. Lauvvang, K. Owre et al., Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: A Phase I/II study with 5 years??? follow-up, Lung Cancer, vol.50, issue.1, pp.97-105, 2005.
DOI : 10.1016/j.lungcan.2005.05.010

Y. Segawa, K. Kiura, N. Takigawa, H. Kamei, S. Harita et al., Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy With Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy With Concurrent Thoracic Radiotherapy in Locally Advanced Non???Small-Cell Lung Cancer: OLCSG 0007, Journal of Clinical Oncology, vol.28, issue.20, pp.3299-306, 2010.
DOI : 10.1200/JCO.2009.24.7577

A. Inca and H. , Référentiel de bon usage de la liste hors GHS : cancers bronchiques et mésothéliomes pleuraux malins, Disponibilité sur Internet, 2009.

J. Treat, R. Gonin, M. Socinski, M. Edelman, R. Catalano et al., A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer, Annals of Oncology, vol.1, issue.3, pp.540-547, 2010.
DOI : 10.1002/1097-0142(197402)33:2<492::AID-CNCR2820330225>3.0.CO;2-O

C. Reynolds, C. Obasaju, M. Schell, X. Li, Z. Zheng et al., Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.27, issue.34, pp.5808-5823, 2009.
DOI : 10.1200/JCO.2009.21.9766

P. Kosmidis, H. Kalofonos, C. Christodoulou, K. Syrigos, T. Makatsoris et al., Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group, Annals of Oncology, vol.19, issue.1, pp.115-137, 2008.
DOI : 10.1093/annonc/mdm430

N. Helbekkmo, S. Sundstrøm, U. Aasebø, P. Brunsvig, V. Plessen et al., Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity, British Journal of Cancer, vol.16, issue.3, pp.283-292, 2007.
DOI : 10.1016/S0169-5002(03)00233-2

P. Kosmidis, N. Mylonakis, C. Nicolaides, C. Kalophonos, E. Samantas et al., Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non???Small-Cell Lung Cancer: A Phase III Randomized Trial, Journal of Clinical Oncology, vol.20, issue.17, pp.3578-85, 2002.
DOI : 10.1200/JCO.2002.12.112

E. Laack, N. Dickgreber, T. Müller, A. Knuth, J. Benk et al., Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer: From the German and Swiss Lung Cancer Study Group, Journal of Clinical Oncology, vol.22, issue.12, pp.2348-56, 2004.
DOI : 10.1200/JCO.2004.10.576

V. Alberola, C. Camps, M. Provencio, D. Isla, R. Rosell et al., Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non???Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial, Journal of Clinical Oncology, vol.21, issue.17, pp.3207-3220, 2003.
DOI : 10.1200/JCO.2003.12.038

A. Inca and H. , Référentiel de bon usage de la liste hors GHS : cancers bronchiques et mésothéliomes pleuraux malins [en ligne]. Décembre, Disponibilité sur Internet, 2011.

P. Amiel, A. Bouregba, A. Hirsch, F. Larra, and M. Rocher, Membres du comité éthique et cancer) Avis n°17 du 30 septembre 2011 « Du bon usage des molécules onéreuses en cancérologie et avis sur les choix inhérents aux contraintes imposées par le coût de ces molécules, Bulletin Ethique et cancer. déc, vol.9, pp.4-5, 2011.